HK:0512 Stock Latest News
Company AnnouncementsGrand Pharmaceutical Proposes Auditor Switch to Deloitte to Support Overseas Expansion1w ago0512
Company AnnouncementsGrand Pharmaceutical’s Interim Results Highlight Nuclear Medicine Surge and Innovation-Driven Growth2M ago0512
Company AnnouncementsGrand Pharmaceutical Schedules Board Meeting to Approve Interim Results2M ago0512
Company AnnouncementsGrand Pharmaceutical Wins FDA Fast Track Status for Innovative Tumor Imaging Drug2M ago0512
Company AnnouncementsGrand Pharmaceutical Shifts Bermuda Registered Office and Share Registrar3M ago0512
Company AnnouncementsGrand Pharmaceutical Advances Innovative TCM Antidepressant into Phase III Trial in China3M ago0512Company AnnouncementsGrand Pharmaceutical formalizes Huadong Medicine supply deal as continuing connected transaction4M ago0512
Company AnnouncementsGrand Pharmaceutical Shareholders Approve All AGM Resolutions, Back Dividend and Mandates4M ago0512
Company AnnouncementsGrand Pharmaceutical Moves to Adopt New Bye-Laws Aligned With HK Paperless Regime6M ago0512
Company AnnouncementsGrand Pharmaceutical Sets 2026 AGM, Proposes Dividend and New Share Mandate6M ago0512
Company AnnouncementsGrand Pharmaceutical Bolsters Liver Cancer Portfolio as Y-90 Trial Hits Key Endpoint in U.S.6M ago0512- Company AnnouncementsGrand Pharmaceutical Deepens HKU Ties as 2026 Innovation Pipeline Takes Shape6M ago0512
Company AnnouncementsGrand Pharmaceutical Lifts Revenue, Boosts Innovative Mix Amid Margin Pressure7M ago0512
Company AnnouncementsGrand Pharmaceutical Wins China Phase II Trial Nod for Innovative Migraine TCM7M ago0512
- Company AnnouncementsGrand Pharmaceutical Warns of 2025 Profit Slump as It Accelerates Shift to Innovative Drugs7M ago0512
Company AnnouncementsGrand Pharmaceutical Secures HK$0.8 Billion Loan Tied to Ownership Stability7M ago0512
Company AnnouncementsGrand Pharmaceutical Sets March 2026 Board Meeting to Approve 2025 Results and Final Dividend7M ago0512
Company AnnouncementsGrand Pharmaceutical Clarifies Valuation Basis for RMB316 Million API Assets Acquisition9M ago0512Company AnnouncementsGrand Pharmaceutical Wins NMPA Acceptance for Prostate Cancer Imaging Drug TLX591-CDx9M ago0512
Company AnnouncementsGrand Pharmaceutical to Acquire Two Biotech and Fine Chemical Units in RMB316 Million Connected Deal10M ago0512
